Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase(R) Closes Non-Brokered Private Placement

Accesswire 7 days ago

Theralase(R) Extends Warrants

Accesswire 10 days ago

Three Canadian small-caps stocks for a contrarian investment

Trevor Abes  October 11, 2024

Latest data from bladder cancer study to propel future growth

Jocelyn Aspa October 10, 2024

Theralase’s bladder cancer drug under investigation in clinical study

Jonathon Brown October 7, 2024

Theralase(R) Provides Update on Bladder Cancer Clinical Study

Accesswire October 7, 2024

Theralase(R) Closes Non-Brokered Private Placement and Issues Stock Options

Accesswire September 24, 2024

Theralase(R) Extends Warrants

Accesswire September 19, 2024

Ruvidar(TM) Proven More Effective Than Acyclovir in Destruction of Herpes Simplex Virus

Accesswire September 3, 2024

Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer

Accesswire August 28, 2024

Pharma stock Theralase paves way for in-home cancer treatment

Trevor Abes  August 21, 2024

Theralase(R) Demonstrates Unique Ability to Activate Rutherrin(R) With Diabetes Drug

Accesswire August 21, 2024

Theralase(R) Release's 2Q2024 Financial Statements

Accesswire August 12, 2024

Theralase(R) Closes $CAN 775,000 in First Tranche of Non-Brokered Private Placement

Accesswire July 8, 2024

Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy

Accesswire June 20, 2024

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

Accesswire June 19, 2024

Theralase adds cancer immunotherapy to potential revenue streams

Trevor Abes  June 18, 2024

Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

Accesswire June 18, 2024

Reminder Notice of Annual General and Special Meeting for Shareholders of Theralase(R)

Accesswire June 14, 2024

Rutherrin(R) Increases Efficacy of Chemotherapy

Accesswire June 12, 2024